A recent Oncology digest,
as sent to subscribers

Study Type: Computational model development and validation study

Key Question: Can a new computational framework (BRIDGE) predict pathological complete response to neoadjuvant breast cancer therapy using tumor transcriptomics or histopathology slides?

Key Findings:

• BRIDGE outperformed established commercial signatures across breast cancer subtypes: ROC-AUC 0.84 (OR=8) in ER+/HER2- tumors, 0.77 (OR=8.3) in HER2+ disease, and 0.73 (OR=3.1) in triple-negative breast cancer
• BRIDGE-Slide applies the framework to standard H&E histopathology slides using deep learning, offering potential for rapid, low-cost biomarker testing
• Training involved 10 transcriptomics datasets with validation across 24 independent cohorts plus 6 histopathology datasets

Clinical Relevance: This could provide the first validated molecular biomarker for neoadjuvant breast cancer response prediction, potentially enabling treatment personalisation and early decision-making in NHS breast cancer services.

Limitations: Requires prospective validation before clinical implementation, and generalizability to immunotherapy combinations needs confirmation in larger cohorts.

Study Type: Single-arm prospective trial with external control comparison

Key Question: Does temporary interruption of adjuvant endocrine therapy to allow pregnancy increase breast cancer recurrence risk in young women with hormone receptor-positive early breast cancer?

Key Findings:

• At median 71 months follow-up, 5-year breast cancer-free interval was 12.3% vs 13.2% in external controls (difference -0.9%, 95% CI -4.2% to 2.6%)
• 5-year distant recurrence-free interval was 6.2% vs 8.3% in controls (difference -2.1%, 95% CI -4.5% to 0.4%)
• 76% of women achieved pregnancy, with 69% having live births and 440 offspring

Clinical Relevance: Provides reassuring longer-term data for counselling young breast cancer patients about fertility preservation and treatment interruption for pregnancy, supporting shared decision-making in this challenging population.

Limitations: Single-arm design relies on external historical controls rather than randomised comparison, limiting strength of safety conclusions.

Study Type: Randomized controlled trial (7-year follow-up analysis)

Key Question: What are the long-term efficacy and safety outcomes of first-line lorlatinib versus crizotinib in advanced ALK-positive NSCLC?

Key Findings:

• Median PFS not reached with lorlatinib vs 9.1 months with crizotinib (HR 0.19, 95% CI 0.13-0.26); 7-year PFS rates 55% vs 3%
• Patients progression-free at 24 months on lorlatinib had 79% probability of remaining progression-free at 7 years
• No new intracranial progression events occurred after 30 months on lorlatinib; median time to intracranial progression not reached vs 16.4 months (HR 0.06)

Clinical Relevance: These unprecedented long-term results support lorlatinib as optimal first-line therapy for ALK-positive NSCLC patients within NHS England's current commissioning arrangements, potentially transforming this into a chronic condition.

Limitations: Overall survival data remains immature with insufficient events for definitive analysis.

Study Type: Randomized controlled trial (phase III)

Key Question: Does adding carboplatin to standard anthracycline-taxane chemotherapy improve outcomes in patients with early-stage triple-negative breast cancer?

Key Findings:

• Carboplatin addition significantly improved event-free survival (HR 0.67, 95% CI 0.49-0.92, p=0.012) with 5-year rates increasing from 75.1% to 82.3%
• Overall survival, invasive disease-free survival, and distant recurrence-free survival showed favourable trends but did not reach statistical significance
• Grade ≥3 adverse events increased from 56.7% to 74.7%, primarily due to haematological toxicity

Clinical Relevance: This supports incorporating carboplatin into standard chemotherapy regimens for early TNBC patients, potentially informing treatment protocols in UK breast cancer services.

Limitations: Secondary survival endpoints did not achieve statistical significance despite consistent directional benefits.

Study Type: Clinical practice guideline update

Key Question: What are the updated recommendations for colorectal cancer screening in average-risk adults, particularly regarding new molecular-based screening tests?

Key Findings:

• Screening age remains 45-75 years for average-risk adults with >10-year life expectancy
• New multitarget stool RNA and next-generation multitarget stool DNA tests demonstrate high sensitivity for CRC and moderate sensitivity for advanced precancerous lesions, recommended as preferred stool-based options at 3-year intervals
• Blood-based cell-free DNA assays show lower sensitivity for advanced precancerous lesions and stage I cancers compared to established stool tests, recommended only for patients declining preferred screening methods

Clinical Relevance: These updated American guidelines may influence UK screening policy discussions, particularly regarding emerging molecular tests and blood-based screening options for patients reluctant to use current NHS screening methods.

Limitations: Guidelines based on modelling studies rather than long-term clinical outcome data for newer molecular tests.

Study Type: Multicentre randomised non-comparative phase II trial

Key Question: What is the efficacy and safety of neoadjuvant dose-dense MVAC combined with durvalumab ± tremelimumab in muscle-invasive bladder cancer?

Key Findings:

• Pathological complete response rates were 48.7% (95% CI 35.9-61.6%) with ddMVAC + durvalumab and 46.3% (95% CI 33.9-58.9%) with the triplet combination
• Grade ≥3 treatment-related adverse events occurred in 30.5% (doublet) vs 49.6% (triplet), with immune-related AEs in 26.9% overall
• PD-L1-high tumours showed superior pCR rates (68.3%) compared to PD-L1-low/negative tumours (33.5%)

Clinical Relevance: This demonstrates promising activity for chemoimmunotherapy combinations in neoadjuvant bladder cancer treatment, potentially relevant as NICE evaluates newer systemic therapy options for muscle-invasive disease.

Limitations: Non-comparative design prevents direct efficacy comparison between treatment arms and lacks a standard chemotherapy control group.

Study Type: Clinical practice guideline (ASCO Living Guideline)

Key Question: What are the current evidence-based treatment recommendations for stage IV non-small cell lung cancer patients with driver alterations?

Key Findings:

• This is a living guideline framework that will be continuously updated as new evidence emerges for targeted therapies in driver-altered NSCLC
• Specific treatment recommendations are not detailed in this abstract - full guidelines accessible via provided URL
• Updates will be published regularly by a standing expert panel using systematic literature review methodology

Clinical Relevance: Provides UK oncologists with access to continuously updated, evidence-based treatment recommendations for molecularly-defined advanced NSCLC, complementing existing NICE guidance in this rapidly evolving therapeutic landscape.

Limitations: The abstract provides only methodological framework without specific clinical recommendations or supporting evidence.

Study Type: Commentary/editorial

Key Question: How do the uncertainties inherent in oncology practice mirror themes found in speculative fiction, particularly regarding the distinction between evidence-based knowledge and hope?

Key Findings:

• Explores parallels between oncology clinical practice and speculative fiction themes
• Examines the philosophical tension between empirical medical knowledge and patient/clinician hope
• Addresses the psychological challenges faced by both oncologists and patients in navigating clinical uncertainty

Clinical Relevance: Provides a reflective framework for UK oncologists to consider how they communicate uncertainty and manage the emotional complexities of cancer care within NHS practice.

Limitations: As a commentary piece, this represents personal reflection rather than empirical research findings.